Scholarlink

<p>Modest outcomes from pharmacogenomic (PGx) testing in depression may be influenced by low rates of actionable gene-drug interactions. This 12-week pilot pragmatic randomized clinical trial evaluated the effectiveness of selectively targeting PGx testing to depressed Veterans receiving psychiatric polypharmacy with an antidepressant on the Sanford Pharmacogenomics Panel. 60&#xa0;Veterans were randomized to having their PGx test results available immediately or delayed until the end of the 12-week trial. Patient Health Questionnaire-9 (PHQ-9) scores were assessed monthly by blinded raters, with medication changes assessed via the electronic medical record. 30% of subjects had an actionable gene-drug interaction, compared to 20% in prior PGx research in Veterans. There were no significant differences in PHQ-9 scores, proportion of patients with medication changes, or time to first medication change. This study showed that targeted PGx testing can increase rates of actionable genotypes in patients with depression.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A pilot study of pharmacogenomic testing as a tool to enhance depression care in Veterans

  • 期刊论文

  • 发表日期：

    2026年4月14日

查看全文
  • Kevin P. Kennedy,
  • Kevin G. Lynch,
  • Ryan Bremseth-Vining,
  • Charlotte E. Williams,
  • Deepak Voora,
  • David W. Oslin

摘要

Modest outcomes from pharmacogenomic (PGx) testing in depression may be influenced by low rates of actionable gene-drug interactions. This 12-week pilot pragmatic randomized clinical trial evaluated the effectiveness of selectively targeting PGx testing to depressed Veterans receiving psychiatric polypharmacy with an antidepressant on the Sanford Pharmacogenomics Panel. 60 Veterans were randomized to having their PGx test results available immediately or delayed until the end of the 12-week trial. Patient Health Questionnaire-9 (PHQ-9) scores were assessed monthly by blinded raters, with medication changes assessed via the electronic medical record. 30% of subjects had an actionable gene-drug interaction, compared to 20% in prior PGx research in Veterans. There were no significant differences in PHQ-9 scores, proportion of patients with medication changes, or time to first medication change. This study showed that targeted PGx testing can increase rates of actionable genotypes in patients with depression.